See more : Mercedes-Benz Group AG (MBGAF) Income Statement Analysis – Financial Results
Complete financial analysis of Cutera, Inc. (CUTR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cutera, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- ASJ Inc. (2351.T) Income Statement Analysis – Financial Results
- Lamar Advertising Company (LAMR) Income Statement Analysis – Financial Results
- Midland States Bancorp, Inc. (MSBI) Income Statement Analysis – Financial Results
- Kartonsan Karton Sanayi ve Ticaret A.S. (KARTN.IS) Income Statement Analysis – Financial Results
- Barings Emerging EMEA Opportunities Plc (BEMO.L) Income Statement Analysis – Financial Results
Cutera, Inc. (CUTR)
About Cutera, Inc.
Cutera, Inc., a medical device company, researches, develops, manufactures, markets, and services laser and energy-based aesthetics systems for practitioners worldwide. The company offers Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for deep dermal remodeling; truSculpt flex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; excel V+, a vascular and benign pigmented lesion treatment platform; truSculpt iD, for the non-surgical body sculpting market; and Secret RF, a fractional RF microneedling system for tissue coagulation and hemostasis. It also provides enlighten platform, a laser system that is used for tattoo removal, as well as to treat benign pigmented lesions and acne scars; excel HR platform, a hair removal solution for various skin types; and xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity. In addition, the company distributes skincare products; and offers post-warranty services through extended service contracts or direct billing. Further, it provides pulsed light hand pieces for the treatment of discoloration, hair removal, and vascular treatments; and Pearl and Pearl Fractional hand pieces, as well as sells hand piece refills, cycle refills, consumable tips, and marketing brochures through the company's website. The company markets and sells its products through direct sales force to plastic surgeons, dermatologists, gynecologists, family practitioners, primary care physicians, and other qualified practitioners, as well as for physicians performing aesthetic treatments in non-medical offices. Cutera, Inc. was incorporated in 1988 and is headquartered in Brisbane, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 212.37M | 252.40M | 231.27M | 147.68M | 181.71M | 162.72M | 151.49M | 118.06M | 94.76M | 78.14M | 74.59M | 77.28M | 60.29M | 53.27M | 53.68M | 83.38M | 101.73M | 100.69M | 75.62M | 52.64M | 39.09M | 28.33M | 19.33M | 9.53M |
| Cost of Revenue | 170.88M | 112.57M | 98.17M | 71.91M | 83.55M | 82.34M | 65.38M | 49.92M | 40.48M | 34.77M | 32.71M | 35.74M | 25.98M | 23.06M | 21.76M | 32.36M | 35.00M | 29.86M | 19.79M | 14.69M | 12.32M | 9.99M | 6.94M | 3.37M |
| Gross Profit | 41.49M | 139.83M | 133.11M | 75.77M | 98.16M | 80.38M | 86.11M | 68.14M | 54.28M | 43.37M | 41.88M | 41.54M | 34.31M | 30.22M | 31.92M | 51.02M | 66.72M | 70.83M | 55.83M | 37.95M | 26.77M | 18.34M | 12.39M | 6.17M |
| Gross Profit Ratio | 19.54% | 55.40% | 57.55% | 51.31% | 54.02% | 49.40% | 56.84% | 57.71% | 57.28% | 55.51% | 56.15% | 53.75% | 56.91% | 56.72% | 59.47% | 61.19% | 65.59% | 70.35% | 73.83% | 72.10% | 68.49% | 64.73% | 64.09% | 64.69% |
| Research & Development | 21.41M | 25.16M | 21.57M | 14.32M | 15.09M | 14.36M | 12.87M | 11.23M | 10.73M | 10.54M | 9.22M | 8.43M | 9.14M | 7.00M | 6.81M | 7.55M | 7.17M | 6.47M | 5.07M | 4.14M | 3.45M | 2.99M | 2.11M | 1.54M |
| General & Administrative | 63.31M | 45.92M | 32.95M | 31.51M | 24.03M | 21.00M | 14.09M | 12.94M | 12.13M | 11.20M | 9.94M | 11.28M | 10.10M | 9.58M | 10.32M | 46.62M | 50.00M | 48.08M | 32.78M | 27.40M | 18.16M | 5.42M | 0.00 | 989.00K |
| Selling & Marketing | 113.00M | 106.95M | 76.76M | 52.77M | 71.11M | 58.42M | 52.07M | 41.56M | 35.94M | 32.25M | 27.98M | 28.66M | 25.50M | 24.74M | 24.29M | 35.35M | 38.28M | 32.89M | 24.80M | 19.05M | 0.00 | 8.60M | 5.43M | 2.79M |
| SG&A | 176.32M | 152.86M | 109.71M | 84.28M | 95.14M | 79.42M | 66.16M | 54.51M | 48.07M | 43.45M | 37.92M | 39.94M | 35.60M | 34.31M | 34.61M | 46.62M | 50.00M | 48.08M | 32.78M | 27.40M | 18.16M | 14.02M | 5.43M | 3.78M |
| Other Expenses | 0.00 | -3.68M | -2.41M | 68.00K | 0.00 | 0.00 | 0.00 | -7.00K | -37.00K | -180.00K | 34.00K | 16.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.94M | 1.31M | 1.27M | 0.00 | 0.00 | 2.34M | 0.00 |
| Operating Expenses | 197.72M | 178.02M | 131.28M | 98.60M | 110.23M | 93.77M | 79.03M | 65.74M | 58.80M | 53.99M | 47.14M | 48.37M | 44.74M | 41.32M | 41.42M | 54.17M | 57.17M | 73.49M | 39.16M | 32.80M | 21.61M | 17.01M | 9.88M | 5.32M |
| Cost & Expenses | 368.60M | 290.59M | 229.44M | 170.51M | 193.78M | 176.11M | 144.42M | 115.66M | 99.28M | 88.76M | 79.85M | 84.10M | 70.72M | 64.37M | 63.18M | 86.53M | 92.17M | 103.35M | 58.95M | 47.49M | 33.92M | 27.00M | 16.82M | 8.69M |
| Interest Income | 9.19M | 2.60M | 3.79M | 647.00K | 0.00 | 123.00K | 884.00K | 323.00K | 330.00K | 406.00K | 421.00K | 481.00K | 594.00K | 539.00K | 0.00 | 3.05M | 4.21M | 3.60M | 2.03M | 632.00K | 30.00K | 85.00K | 171.00K | 193.00K |
| Interest Expense | 14.02M | 5.66M | 2.51M | 579.00K | 199.00K | 884.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.58M | 8.47M | 5.49M | 6.51M | 4.46M | 3.04M | 1.02M | 982.00K | 1.19M | 1.34M | 1.30M | 1.61M | 637.00K | 717.00K | 860.00K | 904.00K | 913.00K | 869.00K | 689.00K | 1.96M | 443.00K | 382.00K | 0.00 | 0.00 |
| EBITDA | -140.94M | -65.22M | 58.00K | -16.90M | -10.52M | -12.18M | 8.09M | 3.38M | -3.34M | -9.06M | -3.95M | -4.72M | -9.80M | -10.38M | -7.91M | -2.25M | 10.47M | -2.66M | 17.98M | 5.15M | 5.61M | 1.71M | 2.51M | 844.00K |
| EBITDA Ratio | -66.37% | -15.06% | 0.03% | -14.51% | -5.79% | -7.49% | 2.70% | 2.86% | -3.52% | -11.88% | -5.30% | -6.76% | -16.28% | -19.49% | -14.50% | 1.57% | 10.29% | 17.03% | 23.78% | 13.51% | 14.34% | 6.04% | 12.99% | 8.86% |
| Operating Income | -156.23M | -38.19M | -1.29M | -22.83M | -12.06M | -13.39M | 11.08M | 2.40M | -4.52M | -10.62M | -5.26M | -6.83M | -10.43M | -11.10M | -10.34M | -3.15M | 9.56M | -2.66M | 16.67M | 5.15M | 5.16M | 1.33M | 2.51M | 844.00K |
| Operating Income Ratio | -73.57% | -15.13% | -0.56% | -15.46% | -6.64% | -8.23% | 7.31% | 2.03% | -4.77% | -13.59% | -7.05% | -8.83% | -17.30% | -20.83% | -19.27% | -3.78% | 9.39% | -2.64% | 22.05% | 9.79% | 13.21% | 4.70% | 12.99% | 8.86% |
| Total Other Income/Expenses | -5.07M | -42.51M | 1.56M | -579.00K | -199.00K | -123.00K | 884.00K | 323.00K | 293.00K | 226.00K | 455.00K | 497.00K | 614.00K | 583.00K | 1.57M | -508.00K | 4.21M | 3.60M | 2.03M | 632.00K | 30.00K | 85.00K | 171.00K | 193.00K |
| Income Before Tax | -161.30M | -80.70M | 3.39M | -23.41M | -12.26M | -13.52M | 11.96M | 2.72M | -4.23M | -10.39M | -4.80M | -6.33M | -9.82M | -10.52M | -8.77M | -3.66M | 13.76M | 939.00K | 18.71M | 5.79M | 5.19M | 1.42M | 2.68M | 1.04M |
| Income Before Tax Ratio | -75.95% | -31.97% | 1.46% | -15.85% | -6.75% | -8.31% | 7.89% | 2.30% | -4.46% | -13.30% | -6.44% | -8.19% | -16.28% | -19.74% | -16.34% | -4.39% | 13.53% | 0.93% | 24.74% | 10.99% | 13.29% | 5.00% | 13.87% | 10.88% |
| Income Tax Expense | 1.53M | 1.64M | 1.32M | 470.00K | 85.00K | 17.26M | -18.03M | 143.00K | 212.00K | 219.00K | -54.00K | 218.00K | 243.00K | 2.00K | 8.91M | -792.00K | 3.26M | -1.18M | 4.91M | 2.03M | 2.09M | 755.00K | 342.00K | 0.00 |
| Net Income | -162.83M | -82.34M | 2.06M | -23.88M | -12.35M | -30.77M | 29.99M | 2.58M | -4.44M | -10.61M | -4.75M | -6.55M | -10.06M | -10.52M | -17.68M | -2.87M | 10.50M | 2.12M | 13.80M | 3.76M | 3.11M | 660.00K | 2.34M | 1.04M |
| Net Income Ratio | -76.67% | -32.62% | 0.89% | -16.17% | -6.80% | -18.91% | 19.80% | 2.18% | -4.69% | -13.58% | -6.36% | -8.47% | -16.69% | -19.74% | -32.93% | -3.44% | 10.33% | 2.11% | 18.25% | 7.14% | 7.95% | 2.33% | 12.10% | 10.88% |
| EPS | -8.19 | -4.39 | 0.12 | -1.43 | -0.88 | -2.23 | 2.16 | 0.19 | -0.32 | -0.74 | -0.33 | -0.46 | -0.73 | -0.78 | -1.33 | -0.22 | 0.80 | 0.17 | 1.20 | 0.38 | 1.47 | 0.36 | 0.38 | 0.18 |
| EPS Diluted | -8.19 | -4.39 | 0.11 | -1.43 | -0.88 | -2.23 | 2.04 | 0.19 | -0.32 | -0.74 | -0.33 | -0.46 | -0.73 | -0.78 | -1.33 | -0.22 | 0.74 | 0.15 | 1.00 | 0.31 | 0.35 | 0.07 | 0.27 | 0.13 |
| Weighted Avg Shares Out | 19.89M | 18.75M | 17.89M | 16.69M | 14.10M | 13.77M | 13.87M | 13.23M | 13.88M | 14.25M | 14.42M | 14.09M | 13.81M | 13.54M | 13.28M | 12.77M | 13.15M | 12.56M | 11.54M | 8.57M | 2.11M | 1.81M | 1.48M | 1.06M |
| Weighted Avg Shares Out (Dil) | 19.89M | 18.75M | 18.36M | 16.69M | 14.10M | 13.77M | 14.73M | 13.75M | 13.96M | 14.25M | 14.42M | 14.09M | 13.81M | 13.54M | 13.28M | 12.77M | 14.23M | 14.28M | 13.86M | 12.22M | 8.84M | 8.81M | 8.73M | 8.01M |
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Cutera, Inc. with Losses of $100,000 to Contact the Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cutera, Inc. - CUTR
JULY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Cutera, Inc. with Losses of $100,000 to Contact the Firm
ROSEN, A TOP RANKED LAW FIRM, Encourages Cutera, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - CUTR
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Cutera, Inc. with Losses of $100,000 to Contact the Firm
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cutera, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - CUTR
CUTERA SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS
Cutera, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Cutera, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CUTR
FDA Clears AviClear® as a Long-Term Treatment for Mild to Severe Acne
Source: https://incomestatements.info
Category: Stock Reports